Costs of New Treatments for Hepatitis C Infection

Lopert, Ruth; Welch, Craig

doi:10.1001/jama.2014.14337

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Policy makers and the public should also be wary about arguments that “acquisition costs” in the pharmaceutical sector represent investment in drug development. Much of the cost of acquiring firms that have developed promising new drugs—such as Gilead’s $11bn acquisition of Pharmasset in 2011—is a business investment in an intangible asset not an investment in research and development 25…”

Section: Concerning Trendsmentioning

confidence: 99%

Pricing of pharmaceuticals is becoming a major challenge for health systems

Morgan

Bathula

Moon

2020

BMJ

View full text Add to dashboard Cite

Achieving FAir Pricing oF Medicines Pricing of pharmaceuticals is becoming a major challenge for health systems Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable, argue Steven Morgan and colleagues P harmaceutical innovations over the past half century have enabled effective treatment and prevention of a wide range of illnesses. These advances were so important in modern healthcare that equitable access to them has been deemed to be a fundamental human right. 1 Fulfilling that right creates tremendous social value but poses a significant policy challenge owing to its costs. Global expenditure on pharmaceuticals reached $1.135tn in 2017, up 56% from 2007. 2 Although demand for medicines is one of the drivers of pharmaceutical expenditure, rising prices are a primary concern for health system managers because medicines are increasingly being priced at levels that appear "unfair." In this article, we review evidence that drug prices often exceed value for money and reasonable compensation for firms' investment in research. We argue that pharmaceutical pricing is a growing challenge for all countries, calling into question the sustainability of the systems that are supposed to drive pharmaceutical innovation.

show abstract

Section: Concerning Trendsmentioning

confidence: 99%